Drugs / KT-579
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07412288 Comparator | Feb → Dec 2026 expected | — | Kymera Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT-579 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07412288 ↗ |
| Route | Oral | “Orally Administered KT-579” NCT07412288 ↗ |